September 13, 2019 — The Akesis Galaxy, a gamma stereotactic radiosurgery (SRS) system with continuous 360-degree rotational technology, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), making the system available to clinicians in the United States.
For patients, the Akesis Galaxy offers efficient delivery of high-precision intracranial treatments thanks to the patented, continuous 360-degree rotational technology. The system offers a large choice of automated collimator selections to build more complex composite shots, “shrink-wrapping” the dose distribution to the target. With only 30 gamma sources, the Galaxy lowers the total cost of ownership and reduces downtime during source replacement.
The Akesis Galaxy builds on isometric design principles that have been published in more than 2,000 peer-reviewed papers for Co-60 based radiosurgery. With < 0.5mm radiologic accuracy, Akesis Galaxy also provides sharp dose fall-off, with potentially better sparing of organs at risk.
The system is an ideal solution for high-throughput institutions, smaller cancer centers and value-based reimbursement models.
The Akesis Galaxy will be on display at the American Society for Radiation Oncology (ASTRO) 2019 annual meeting, Sept. 15-18 in Chicago.
For more information: www.akesis.com
January 22, 2026 
